Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 1 minute read Pharma Industry News Biocon Biologics signs licensing deal for two biosimilars with Yoshindo Biocon Ltd. said that its subsidiary Biocon Biologics has signed an out-licensing agreement with Japanese pharma company Yoshindo… byPallavi MadhirajuOctober 17, 2022